Glossary
The state-of-the-art glossary for Waldenström’s macroglobulinemia.
Zanubrutinib
Zanubrutinib in the glossary for Waldenström's macroglobulinemia
A small molecule second-generation inhibitor of Bruton's tyrosine kinase
Zanubrutinib is a small-molecule inhibitor of Bruton's tyrosine kinase (BTK). Zanubrutinib is approved for the treatment of mantle cell lymphoma (MCL) in ten countries, including China, Canada, Australia and Russia.1 It is also approved for the treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in China. 1 Zanubrutinib is approved in the EU, UK and Australia for the treatment of adult patients with WM who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. 1,2,3
Glossary overview